---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-418538"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-10-09T11:59:32+00:00"
generated_at: "2026-10-12T15:18:26.059001+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics renamed IRulya; Roberts named CEO, Militello CFO, Fandrick COO effective Oct 8, 2026

## Summary
- Brigette Roberts, M.D. became CEO effective Oct 8, 2026 with $600,000 base salary and 50% target bonus; John Militello, CPA became CFO and Keith Fandrick, Ph.D. became COO.
- Dirk Thye resigned as CEO, CMO and director and Brendan Hannah resigned as COO, CBO and CCO; June Bray, David Lamond, Christopher Senner and Thye also left the Board with no disagreements.
- Name change to IRulya Therapeutics Inc. is effective 4:01 p.m. ET Oct 9, 2026; common stock moves to Nasdaq Capital Market under IRLA effective Oct 12, 2026, with CUSIP unchanged.
- Cash balance was $116 million as of June 30, 2026 and is expected to fund operations through end of 2028, supporting Phase 2 data readouts for LAM-001 in BOS, PH-ILD and SAPH.
- Board added Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise effective Oct 8, 2026; Patterson chairs Audit/Compensation, Valentine chairs Governance.

## SEC filing metadata
- accession: 0001193125-26-418538
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-10-09T11:59:32+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/d172110d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-418538
- JSON: https://secwatch.observer/filing/0001193125-26-418538.json
- Plain text: https://secwatch.observer/filing/0001193125-26-418538.txt

## Key facts
- Executive change
  Dirk Thye resigned as Chief Executive Officer, Chief Medical Officer and Director at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer, Chief Medical Officer and Director
  source text: effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm
- Executive change
  Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Operating Officer, Chief Business Officer and Chief Compliance Officer
  source text: Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm
- Executive change
  Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective October 8, 2026 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.